Pfizer's COVID vaccine (Comirnaty) is fully approved for patients ages 12 and up, and authorized for kids ages 6 months ...

Novavax's growth relies on Sanofi royalties and COVID/flu vaccines, lacking innovation and clear catalysts. Click here to ...

Novavax Inc. closed 61.59% short of its 52-week high of $17.81, which the company achieved on July 26th.

The FDA's Dr. Vinay Prasad said that he disagreed with the agency's career vaccine reviewers about COVID shot approvals.

Novavax Inc. (NASDAQ:NVAX) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On June 17, Citi initiated ...

Buying shares of beaten-down companies only makes sense if there are good reasons to expect them to bounce back. If that's not the case, stocks that may look cheap and attractive aren't actually so.

Novavax Inc. closed 60.47% below its 52-week high of $17.81, which the company achieved on July 26th.

Novavax (NVAX) closed the most recent trading day at $6.61, moving -2.79% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 0.79% for the day. At the ...

A top official at the Food and Drug Administration recently overruled government scientists on the availability of two ...

A top official at the Food and Drug Administration recently overruled government scientists on the availability of two ...

Moderna's Spikevax receives FDA approval for use in high-risk children; Pfizer, BioNTech appeal U.K. ruling in COVID-19 ...

Novavax, Inc. faces profitability challenges despite a promising tech platform, with uncertain revenue streams. Click for my NVAX stock update.